Trial · NCT03832595
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD) | Intervention Arm | 9.7 | 95% Confidence Interval 6.6 to 12.7 | percent | |
| Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD) | Usual Care | 10.9 | 95% Confidence Interval 7.7 to 14.1 | percent | |
| Hypertension (HTN) Control Outcome | Intervention Arm | 0.011 | 95% Confidence Interval -0.002 to 0.024 | log-odds per month slope | |
| Hypertension (HTN) Control Outcome | Usual Care | 0.0005 | 95% Confidence Interval -0.012 to 0.013 | log-odds per month slope | |
| Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) Exposure Days Per Year | Intervention Arm | 196.8 | 95% Confidence Interval 174.9 to 219.0 | exposure days per year | |
| Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) Exposure Days Per Year | Usual Care | 163.1 | 95% Confidence Interval 146.3 to 179.9 | exposure days per year | |
| Medication Safety: Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Exposure Days Per Year | Intervention Arm | 5.3 | 95% Confidence Interval 2.6 to 8.0 | exposure days per year | |
| Medication Safety: Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Exposure Days Per Year | Usual Care | 6.7 | 95% Confidence Interval 3.7 to 9.7 | exposure days per year | |
| Medication Safety: Glyburide Exposure Days Per Year | Intervention Arm | 2.4 | 95% Confidence Interval -3.7 to 8.5 | exposure days per year | |
| Medication Safety: Glyburide Exposure Days Per Year | Usual Care | 2.0 | 95% Confidence Interval -1.6 to 5.7 | exposure days per year | |
| Medication Safety: Metformin Exposure Days Per Year | Intervention Arm | 17.8 | 95% Confidence Interval -6.5 to 42.2 | exposure days per year | |
| Medication Safety: Metformin Exposure Days Per Year | Usual Care | 16.0 | 95% Confidence Interval -1.7 to 33.6 | exposure days per year | |
| Subgroup Analysis: Use of Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) (Outcome 3) in Participants With UACR ≥300 mg/g | Usual Care | 177.5 | 95% Confidence Interval 146.2 to 208.8 | medication exposure days per year | |
| Subgroup Analysis: Use of Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) (Outcome 3) in Participants With UACR ≥300 mg/g | Intervention Arm | 222.5 | 95% Confidence Interval 182.9 to 262.1 | medication exposure days per year | |
| Hypertension (HTN) Control for Achieved BP <130/80 mm Hg | Intervention Arm | 0.086 | 95% Confidence Interval 0.073 to 0.100 | log-odds per month slope | |
| Hypertension (HTN) Control for Achieved BP <130/80 mm Hg | Usual Care | 0.079 | 95% Confidence Interval 0.066 to 0.092 | log-odds per month slope |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03832595/results